Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30219774 | 1.00 | TSHR (0.41) | TSHRMAPK1TRPV1GRM4RAPGEF3 | |
| SCHEMBL30219722 | 0.85 | ALDH1A1 (0.43) | TSHRMAPK1ALDH1A1MAPT | |
| SCHEMBL24046641 | 0.85 | ALDH1A1 (0.43) | TSHRMAPK1ALDH1A1MAPT | |
| SCHEMBL11116559 | 0.73 | MAPT (0.50) | FAAHALDH1A1MAPTNPSR1L3MBTL1 | |
| SCHEMBL30219772 | 0.73 | TSHR (0.40) | TSHRMAPK1MRGPRX4ALDH1A1MAPT | |
| SCHEMBL24046632 | 0.73 | TSHR (0.40) | TSHRMAPK1MRGPRX4ALDH1A1MAPT | |
| SCHEMBL11115994 | 0.68 | MAPT (0.53) | TRPV1GRM4FAAHALDH1A1MAPT | |
| SCHEMBL11525237 | 0.68 | KDR (0.43) | TRPV1GRM4RAPGEF3ALDH1A1MAPT | |
| SCHEMBL26304300 | 0.68 | PDE2A (0.44) | RAPGEF3MRGPRX4 | |
| SCHEMBL11118123 | 0.68 | GRM4 (0.41) | TRPV1GRM4FAAHALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192644-A1 | PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192644-A1 | PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2021236885-A1 | PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192644-A1 | PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | IKZF2, IKZF1, NUTF2 | TSHR 4330/4885MAPK1 4270/4885TRPV1 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.